Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › RAY1225

RAY1225

GIP/GLP-1 · s.c. every 2 weeks · Raynovent

Data cut 12 November 2026 · page built 16 November 2026 · 9 trial arms · 4 trials with results · 3 registered trials · see on the pipeline board

Summary

Also known as
Raynovent
Mechanism
GIP/GLP-1
Route
s.c. every 2 weeks
Company
Raynovent
Highest development stage
phase 3
Status (as of data cut)
Phase 3 REBUILDING-2 positive (9 mg every 2 weeks: −22.2 % at 52 weeks, topline Oct 2026); licensed to Qilu verify
Next milestone
NDA in China

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity3 positive phase 3Positive phase 3 REBUILDING-2 (topline Oct 2026)
T2D2 phase 3 ongoingPhase 3 registered on ClinicalTrials.gov
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
REBUILDING-1 (RAY1225, NCT06254261)3 mg Q2Wobesity china24172——−10.1 % vs −3.5 %
estimand not specified
———————press release
REBUILDING-1 (RAY1225, NCT06254261)6 mg Q2Wobesity china24172——−13.0 % vs −3.5 %
estimand not specified
———————press release
REBUILDING-1 (RAY1225, NCT06254261)9 mg Q2Wobesity china24172——−15.1 % vs −3.5 %
estimand not specified
———————press release
SHINING-1 (RAY1225, NCT06254274)3 mg Q2Wt2d china24231——−1.7 vs −0.2——————congress
SHINING-1 (RAY1225, NCT06254274)6 mg Q2Wt2d china24231——−2.0 vs −0.2——————congress
SHINING-1 (RAY1225, NCT06254274)9 mg Q2Wt2d china24231——−2.1 vs −0.2——————congress
SHINING-1 (RAY1225, NCT06254274)12 mg Q2Wt2d china24231——−2.3 vs −0.2——————congress
Shining-1 (T2D)RAY1225 15 mg every 2 weekst2d china24———−2.8 vs −0.2—————−7.8 vs +0.0verified
REBUILDING-2 (RAY1225, NCT06893016)9 mg Q2Wobesity china52641−22.3 %−22.2 %———————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (10)
  • RAY1225 15 mg every 2 weeks · hba1c · Abstract, Results
    -2.76% (-3.25 to -2.26) in the 3 mg, 6mg, 9mg, 12mg and 15 mg, respectively
  • 9 mg Q2W · weight_tp · HKEX filing
    9mg 组体重较基线降低 22.24%,经安慰剂校正后降低 20.46%
  • 9 mg Q2W · weight_eff · HKEX filing
    补充分析(假想策略)RAY1225 注射液 9mg 组体重较基线降低 22.30%,经安慰剂校正后降低 20.50%
  • 3 mg Q2W · weight_unsp · HKEX filing
    治疗 24 周体重呈剂量依赖性下降,体重较基线相对变化的最小二乘均数分别为-10.05%、-12.98%和-15.05%,安慰剂组为-3.55%
  • 6 mg Q2W · weight_unsp · HKEX filing
    治疗 24 周体重呈剂量依赖性下降,体重较基线相对变化的最小二乘均数分别为-10.05%、-12.98%和-15.05%,安慰剂组为-3.55%
  • 9 mg Q2W · weight_unsp · HKEX filing
    治疗 24 周体重呈剂量依赖性下降,体重较基线相对变化的最小二乘均数分别为-10.05%、-12.98%和-15.05%,安慰剂组为-3.55%
  • 3 mg Q2W · hba1c · abstract
    The changes in HbA1c from baseline to week 24 were -1.66% (95% CI -1.88 to -1.45), -2.04% (-2.26 to -1.82), -2.14% (-2.36 to -
  • 6 mg Q2W · hba1c · abstract
    The changes in HbA1c from baseline to week 24 were -1.66% (95% CI -1.88 to -1.45), -2.04% (-2.26 to -1.82), -2.14% (-2.36 to -
  • 9 mg Q2W · hba1c · abstract
    The changes in HbA1c from baseline to week 24 were -1.66% (95% CI -1.88 to -1.45), -2.04% (-2.26 to -1.82), -2.14% (-2.36 to -
  • 12 mg Q2W · hba1c · abstract
    1.92) , -2.34% (-2.56 to -2.12), -2.76% (-3.25 to -2.26) in the 3 mg, 6mg, 9mg, 12mg and 15 mg, respectively, versus -0.25% (-0.43 to -0.07)

Registered trials (3)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
NCT07139535
A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
T2DPhase 3not yet recruiting2025-08 → 2026-12350not yet recruitingNCT07139535
NCT07139548
A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes
T2DPhase 3not yet recruiting2025-08 → 2026-12600not yet recruitingNCT07139548
NCT06893016
Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight
ObesityPhase 3recruiting2025-06 → 2026-06640recruitingNCT06893016

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: RAY1225. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/ray1225/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.